drugset / Trial / NCT01642667

Pharmacoinvasive Therapy With Prourokinase

NCT01642667

Phase 2/3 Completed 197 enrolled Suzhou Landing Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to elucidate the efficacy and safety of pharmacoinvasive therapy by using prourokinase (prouk), a unique fibrin-specific agent, in patients with ST-segment elevation myocardial infarction (STEMI)

Timeline

Start
2008-11
Primary completion
2009-11
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator prourokinase Protein / enzyme biologic 1.2e+06 iu
Comparator prourokinase Protein / enzyme biologic 4.8e+06 iu